Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics:

• Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00)
• Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09)
• First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03)
• Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31)
• Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59)

NCPD information and select publications

Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo, including the following topics:

• Introduction (0:00)
• Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52)
• Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10)
• Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09)
• Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O’Shaughnessy (1:04:00)
• Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28)
• Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51)

CME information and select publications

Featuring perspectives from Dr Andrea Cercek, Dr Arvind Dasari, Dr J Randolph Hecht, Dr Pashtoon Kasi and Prof Eric Van Cutsem, moderated by Dr Hecht, including the following topics:

• Introduction (0:00)
• Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer (CRC) — Dr Dasari (2:20)
• Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC — Dr Cercek (28:32)
• Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease — Dr Kasi (54:07)
• Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC) — Dr Hecht (1:14:34)
• Identification and Care of Patients with mCRC and Actionable Genomic Alterations — Prof Van Cutsem (1:38:17)

CME information and select publications

Featuring perspectives from Ms Ilene Galinsky, Dr Michael J Mauro, Dr Neil P Shah and Dr Sara M Tinsley-Vance, including the following topics:

• Introduction: Chronic Myeloid Leukemia (CML) as a Model for Targeted Treatment (0:00)
• Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML (12:37)
• Role of Asciminib for Newly Diagnosed CP-CML (47:46)
• Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment (1:14:06)
• Management of CP-CML After Failure of Initial Therapy (1:23:04)

NCPD information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12)
• Current Treatment for Metastatic HSPC — Dr Armstrong (26:12)
• Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31)
• Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51)
• Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11)

CME information and select publications

Featuring an interview with Dr Patrick Y Wen, including the following topics:

• Glioma classification (0:00)
• Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50)
• Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55)
• Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46)
• Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30)
• Current and emergent strategies for the management of glioblastoma (31:27)
• Optimizing patient care and quality of life (46:24)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics:

• Classification and pathologic diagnosis of gliomas (0:00)
• Role of IDH inhibitors in the management of low-grade gliomas (6:37)
• Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53)

CME information and select publications